Molecular mechanisms of ischemic neuronal cell death - With relevance to Alzheimer's disease

Current Alzheimer Research

Volumn 3, Issue 4, 2006, Pages 351-358

  Hayashi, Takeshi ^a   Shoji, Mikio ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Cell death; Ischemia; Organelle

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; GLUTAMATE RECEPTOR ANTAGONIST;

ALZHEIMER DISEASE; APOPTOSIS; CELL DAMAGE; CELL DEATH; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; DRUG MECHANISM; ENDOPLASMIC RETICULUM; HUMAN; LYSOSOME; MEMBRANE POTENTIAL; NERVE CELL MEMBRANE; NEUROPROTECTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; BRAIN; BRAIN ISCHEMIA; HUMANS; MITOCHONDRIAL PROTEINS; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; ORGANELLES; SIGNAL TRANSDUCTION;

EID: 33748446616     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506778249498     Document Type: Review

References (92)

1. Snyder EY and Park KI. Limitations in the brain repair. Nat Med 8: 928-930 (2002).
2. Arvidsson A, Collin T, Kirik D, Kokaia Z and Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 8: 963-970 (2002).
3. Hertz L and Peng L. Energy metabolism at the cellular level of the CNS. Can J Physiol Pharmacol 70: S14 (1992).
4. Bachelard HS. Carbohydrate and energy metabolism of the central nervous system: Biochemical approach. In 'Handbook of Neurology vol 27', North-Holland Publishing Company, Amsterdam, p1 (1976).
5. Garcia JH and Kamijyo Y. Cerebral infarction: Evolution of histopathological changes after occlusion of a middle cerebral artery in primates. Exp Neurol 33: 408-421 (1974).
6. Benveniste H, Drejer J, Schousboe A and Diemer NH. Elevation of the extracellular concentration of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 43: 1369-1374 (1984).
7. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634 (1988).
8. Chan PH, Schmidley JW, Fishman RA and Longar SM. Brain injury, edema, and vascular permeability changes induced by oxygen-derived free radicals. Neurology 34: 315-320 (1984).
9. Lewen A, Matz P and Chan PH. Free radical pathways in CNS injury. J Neurotrauma 17: 871-890 (2000).
10. Schellinger PD, Kaste M and Hacke W. An update on thrombolytic therapy for acute stroke. Curr Opin Neurol 17: 69-77 (2004).
11. Alexandrov AV, Masdeu JC, Devous MD Sr, Black SE and Grotta JC. Brain single-photon emission CT with HMPAO and safety of thrombolytic therapy in acute ischemic stroke. Proceedings of the meeting of the SPECT Safe Thrombolysis Study Collaborators and the members of the Brain Imaging Council of the Society of Nuclear Medicine. Stroke 28:1830-1834 (1997).
12. Cornu C, Amsallem E and Serradj-Jaillard AA. Thrombolytic therapy for acute ischemic stroke. Am J Cardiovasc Drugs 1: 281-92 (2001).
13. Hayashi T and Abe K. Ischemic neuronal cell death and organellae damage. Neurol Res 26: 827-834 (2004).
14. Erecinska M and Silver IA. Loss of neuronal calcium homeostasis in ischemia. In 'Primer on cerebrovascular diseases' (Ed: Welch KMA, Caplan LR, Reis DJ, Siesjo BK and Weir B), Academic Press, San Diego, p178-183 1997.
15. Erecinska M and Silver IA. Ions and energy in mammalian brain. Prog Neurobiol 43: 27-71 (1994).
16. + currents that fail to inactivate. Trends Neurosci 16: 455-460 (1993).
17. Small DL and Buchan AM. NMDA and AMPA receptor antagonists in global and focal ischemia. In 'Primer on cerebrovascular diseases' (Ed: Welch KMA, Caplan LR, Reis DJ, Siesjo BK and Weir B), Academic Press, San Diego, pp. 244-247 (1997).
18. Taft WC, Clifton GL, Blair RE and Delorenzo RJ. Phenytoin protects against ischemia-produced neuronal cell death. Brain Res 483: 143-148 (1989).
19. Crumrine RC, Bergstrand K, Cooper AT, Faison WL, Cooper BR. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke 28: 2230-2236 (1997).
20. Meldrum B. Sodium channel antagonists. In 'Primer on cerebrovascular diseases' (Ed: Welch KMA, Caplan LR, Reis DJ, Siesjo BK and Weir B), Academic Press, San Diego, pp. 248-250 (1997).
21. Desphande JK, Siesjo BK and Wieloch T. Calcium accumulation and neuronal damage in the rat hippocampus following cerebral ischemia. J Cereb Blood Flow Metab 7: 89-95 (1987).
22. Siesjo BK and Kristian T. Cell calcium homeostasis and calcium-related ischemic damage. In 'Primer on cerebrovascular diseases' (Ed: Welch KMA, Caplan LR, Reis DJ, Siesjo BK and Weir B), Academic Press, San Diego, pp. 172-178 (1997).
23. Kristian T, Gido G, Kuroda S, Schutz A and Siesjo BK. Calcium metabolism of focal and penumbral tissues in rats subjected to transient middle cerebral artery occlusion. Exp Brain Res 120: 503-509 (1998).
24. Germano IM, Bartkowski HM, Cassel ME and Pitts LH. The therapeutic value of nimodipine in experimental focal cerebral ischemia. Neurological outcome and histopathological findings. J Neurosurg 67: 81-87 (1987).
25. Horn J and Limburg M. Calcium antagonists for ischemic stroke. A systematic review. Stroke 32: 570-576 (2001).
26. Veeranna, Kaji T, Boland B, Odrljin T, Mohan P, Basavarajappa BS, et al. Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. Am J Pathol 165: 795-805 (2004).
27. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 27: 1133-42 (1990).
28. Choi DW. Excitotoxic cell death. J Neurobiol 23: 1261-1276 (1992).
29. Hollmann M and Heinemann S. Cloned glutamate receptors. Ann Rev Neurosci 17: 31-108 (1994).
30. Buchan AM, Lesiuk H, Barnes KA, Li H, Huang ZG, Smith KE, et al. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke 24(Suppl): I148-52 (1993).
31. Park CK, Nehls DG, Graham DI, Teasdale GM and McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol 24: 543-51 (1988).
32. Muir KW, Grosset DG and Lees KR. Clinical pharmacology of CNS 1102 in volunteers. Ann N Y Acad Sci. 765: 279-89 (1995).
33. Gill R. The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. Cerebrovasc Brain Metab Rev 6: 225-256 (1994).
34. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis 6(6 Suppl): S61-74 (2004).
35. Mobius HJ, Stoffler A and Graham SM. Memantine hydrochloride: pharmacological and clinical profile. Drugs Today (Barc) 40: 685-695 (2004).
36. Lindsberg PJ and Kaste M. Thrombolysis for acute stroke. Curr Opin Neurol 16: 73-80 (2003).
37. Liu S, Liu M, Peterson S, Miyake M, Vallyathan V and Liu KJ. Hydroxyl radical formation is greater in striatal core than in penumbra in a rat model of ischemic stroke. J Neurosci Res 71: 882-888 (2003).
38. Hayashi T, Saito A, Okuno S, Ferrand-Drake M, Dodd RL, Nishi T, et al. Oxidative damage to the endoplasmic reticulum is implicated in ischemic neuronal cell death. J Cereb Blood Flow Metab 23: 1117-1128 (2003).
39. Hayashi T, Saito A, Okuno S, Ferrand-Drake M, Dodd RL and Chan PH. Damage to the endoplasmic reticulum and activation of apoptotic machinery by oxidative stress in ischemic neurons. J Cereb Blood Flow Metab 25: 41-53 (2005).
40. Sugawara T, Noshita N, Lewen A, Gasche Y, Ferrand-Drake M, Fujimura M, et al. Overexpression of copper/zinc superoxide dismutase in transgenic rats protects vulnerable neurons against ischemic damage by blocking the mitochondrial pathway of caspase activation. J Neurosci 22: 209-217 (2002).
41. Lewen A, Matz P and Chan PH. Free radical pathways in CNS injury. J Neurotrauma 17:871-890 (2000).
42. Halliwell B and Gutteridge JMC. Oxidative stress: adaptation, damage, repair and death. In: 'Free radicals in biology and medicine'. (Ed: Halliwell B and Gutteridge JMC), Oxford University Press, New York, (1999).
43. Chan PH. Role of oxidants in ischemic brain damage. Stroke 27: 1124-1129 (1996).
44. Chan PH, Kawase M, Murakami K, Chen SF, Li Y, Calagui B, et al. Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischemia and reperfusion. J Neurosci 18: 8292-8299 (1998).
45. Fullerton HJ, Ditelberg JS, Chen SF, Sarco DP, Chan PH, Epstein CJ et al. Copper/zinc superoxide dismutase transgenic brain accumulates hydrogen peroxide after perinatal hypoxia ischemia. Ann Neurol 44: 357-364 (1998).
46. Casadesus G, Smith MA, Zhu X, Aliev G, Cash AD, Honda K, et al. Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis 6: 165-169 (2004).
47. Schuessel K, Schafer S, Bayer TA, Czech C, Pradier L, Muller-Spahn F, et al. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol Dis 18: 89-99 (2005).
48. Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS and Li L. Oxidative Modifications and Aggregation of Cu,Zn-Superoxide Dismutase Associated with Alzheimer and Parkinson Diseases. J Biol Chem 280: 11648-11655 (2005).
49. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 59: 1011-1017 (2000).
50. Abe K, Kawagoe J, Aoki M and Kogure K. Changes of mitochondrial DNA and heat shock protein gene expressions in gerbil hippocampus after transient forebrain ischemia. J Cereb Blood Flow Metab 13: 773-780 (1993).
51. Murakami K, Kondo T, Kawase M, Li Y, Sato S, Chen SF, et al. Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J Neurosci 18: 205-213 (1998).
52. Sugawara T, Fujimura M, Noshita N, Kim GW, Saito A, Hayashi T, et al. Neuronal death/survival signaling pathways in cerebral ischemia. NeuroRx 1: 17-25 (2004).
53. Fujimura M, Morita-Fujimura Y, Murakami K, Kawase M and Chan PH. Cytosolic redistribution of cytochrome c after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 18: 1239-1247 (1998).
54. Saito A, Hayashi T, Okuno S, Nishi T and Chan PH. Oxidative stress is associated with XIAP and Smac/DIABLO signaling pathways in mouse brains after transient focal cerebral ischemia. Stroke 35: 1443-1448 (2004).
55. Matsumoto S, Friberg H, Ferrand-Drake M and Wieloch T. Blockade of the mitochondrial permeability transition pore diminishes infarct size in the rat after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 19: 736-741 (1999).
56. Cao G, Minami M, Pei W, Yan C, Chen D, O'Horo C, et al. Intracellular Bax translocation after transient cerebral ischemia: implications for a role of the mitochondrial apoptotic signaling pathway in ischemic neuronal death. J Cereb Blood Flow Metab 21: 321-333 (2001).
57. De Giorgi F, Lartigue L, Bauer MK, Schubert A, Grimm S, Hanson GT, et al. The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB J 16: 607-609 (2002).
58. Okuno S, Saito A, Hayashi T and Chan PH. The c-Jun N-terminal protein kinase signaling pathway mediates Bax activation and subsequent neuronal apoptosis through interaction with Bim after transient focal cerebral ischemia. J Neurosci 24 : 7879-7887 (2004).
59. Fujimura M, Morita-Fujimura Y, Noshita N, Sugawara T, Kawase M and Chan PH. The cytosolic antioxidant copper/zinc-superoxide dismutase prevents the early release of mitochondrial cytochrome c in ischemic brain after transient focal cerebral ischemia in mice. J Neurosci 20: 2817-2824 (2000).
60. Hirai K, Smith MA, Wade R and Perry G. Neuronal RNA oxidation and mitochondrial proliferation denote profound metabolic abnormalities in Alzheimer disease. Neurobiol Aging 19(Suppl 4S): S4-5 (1998).
61. Bubber P, Haroutunian V, Fisch G, Blass JP and Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57: 695-703 (2005).
62. Sullivan PG and Brown MR. Mitochondrial aging and dysfunction in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 29: 407-410 (2005).
63. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW and Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis 11: 341-354 (2002).
64. Tacconi S, Perri R, Balestrieri E, Grelli S, Bernardini S, Annichiarico R, et al. Increased caspase activation in peripheral blood mononuclear cells of patients with Alzheimer's disease. Exp Neurol 190: 254-262 (2004).
65. Nowak TS Jr, Fried RL, Lust WD and Passonneau JV. Changes in brain energy metabolism and protein synthesis following transient bilateral ischemia in the gerbil. J Neurochem 44: 487-494 (1985).
66. Zhang K and Kaufman RJ. Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem 279: 25935-25938 (2004).
67. Kleijn M, Scheper GC, Voorma HO and Thomas AA. Regulation of translation initiation factors by signal transduction. Eur J Biochem 253: 531-544 (1998).
68. Rowlands AG, Panniers R and Henshaw EC. The catalytic mechanism of guanine nucleotide exchange factor action and competitive inhibition by phosphorylated eukaryotic initiation factor 2. J Biol Chem 263: 5526-5533 (1988).
69. Webb BL and Proud CG. Eukaryotic initiation factor 2B (eIF2B). Int J Biochem Cell Biol 29: 1127-1131 (1997).
70. Althausen S, Mengesdorf T, Mies G, Olah L, Nairn AC, Proud CG, et al. Changes in the phosphorylation of initiation factor eIF-2alpha, elongation factor eEF-2 and p70 S6 kinase after transient focal cerebral ischaemia in mice. J Neurochem 78: 779-787 (2001).
71. de la Vega CM, Burda J and Salinas M. Ischemia-induced inhibition of the initiation factor 2α phosphatase activity in the rat brain. Neuroreport 12: 1021-1025 (2001).
72. Kumar R, Azam S, Sullivan JM, Owen C, Cavener DR, Zhang P, et al. Brain ischemia and reperfusion activates the eukaryotic initiation factor 2α kinase, PERK. J Neurochem 77: 1418-1421 (2001).
73. Hayashi T, Saito A, Okuno S, Ferrand-Drake M, Chan PH. Induction of GRP78 by ischemic preconditioning reduces endoplasmic reticulum stress and prevents delayed neuronal cell death. J Cereb Blood Flow Metab 23: 949-961 (2003).
74. Shen X, Zhang K and Kaufman RJ. The unfolded protein response - a stress signaling pathway of the endoplasmic reticulum. J Chem Neuroanat 28: 79-92 (2004).
75. Hayashi T, Saito A, Okuno S, Ferrand-Drake M, Dodd RL, Chan PH. Oxidative injury to the endoplasmic reticulum in mouse brains after transient focal ischemia. Neurobiol Dis 15: 229-39 (2004).
76. Paschen W and Doutheil J. Disturbances of the functioning of endoplasmic reticulum: a key mechanism underlying neuronal cell injury? J Cereb Blood Flow Metab 19: 1-18 (1999).
77. 2+-transport and protection by stobadine. Biochem Mol Biol Int 36: 569-577 (1995).
78. 2+-ATPase by peroxynitrite. Free Radic Res 24: 243-259 (1996).
79. Li F, Hayashi T, Jin G, Deguchi K, Nagotani S, Nagano I, et al. The protective effect of dantrolene on ischemic neuronal cell death is associated with reduced expression of endoplasmic reticulum stress markers. Brain Res 1048: 59-68 (2005).
80. Mouw G, Zechel JL, Gamboa J, Lust WD, Selman WR, Ratcheson RA. Activation of caspase-12, an endoplasmic reticulum resident caspase, after permanent focal ischemia in rat. Neuroreport 14: 183-186 (2003).
81. Shibata M, Hattori H, Sasaki T, Gotoh J, Hamada J, Fukuuchi Y. Activation of caspase-12 by endoplasmic reticulum stress induced by transient middle cerebral artery occlusion in mice. Neuroscience 118: 491-499 (2003).
82. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 5: 101-106 (1999).
83. Katayama T, Imaizumi K, Honda A, Yoneda T, Kudo T, Takeda M, et al. Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations. J Biol Chem 276: 43446-54 (2001).
84. Imaizumi K, Katayama T and Tohyama M. Presenilin and the UPR. Nat Cell Biol 3: E104 (2001).
85. Katayama T, Imaizumi K, Sato N, Miyoshi K, Kudo T, Hitomi J, et al. Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Bio 1: 479-485 (1999).
86. Katayama T, Imaizumi K, Manabe T, Hitomi J, Kudo T and Tohyama M. Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat 28: 67-78 (2004).
87. Locksin RA and Zakeri Z. Caspase-independent cell deaths. Curr Opin Cell Biol 14: 727-733 (2002).
88. Nixon RA, Cataldo AM and Mathews PM. The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review. Neurochem Res 25: 1161-1172 (2000).
89. Islekel H, Islekel S, Guner G and Ozdamar N. Evaluation of lipid peroxidation, cathepsin L and acid phosphatase activities in experimental brain ischemia-reperfusion. Brain Res 843: 18-24 (1999).
90. Cataldo AM, Barnett JL, Pieroni C and Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci 17: 6142-6151 (1997).
91. Yang AJ, Chandswangbhuvana D, Margol L and Glabe CG. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res 52: 691-698 (1998).
92. de la Torre JC. Is Alzheimer's disease preceded by neurodegeneration or cerebral hypoperfusion? Ann Neurol 57: 783-784 (2005).